RetinalGeniX Technologies contracts with MEDsan to provide diagnostic testing services
January 2nd 2024According to a news release, the services will be provided for RetinalGeniX Technologies’ Institutional Review Board to conduct a study to personalize medical evaluations for patients receiving treatment for wet macular degeneration.
Read More
Medical Administrative Contractors withdraw final LCDs on MIGS
January 2nd 2024All five MACs have now issued statements that the final LCDs will not go into effect on January 29, 2024. The MACs had identified certain procedures as investigational for glaucoma management in patients over the age of 18.
Read More
Sight Sciences publishes results of SAHARA clinical trial for the treatment of dry eye disease
December 21st 2023Interventional eyelid procedures enabled by TearCare technology delivered clinically and statistically significant improvements in every sign and symptom measured at every time point through 6 months.
Read More
Azura CEO gives details on phase 2 study of AZR-MD-001
December 18th 2023Marc Gleeson, CEO of Azura, sat down with David Hutton, Managing Editor at Ophthalmology Times to discuss the recent positive results from the Phase 2 clinical trial of AZR-MD-001 in patients with contact lens discomfort.
Read More
Nicox screens first patient in Whistler Phase 3b trial of NCX 470 in glaucoma
December 18th 2023NCX 470, a novel nitric oxide-donating bimatoprost eye drop, is the company’s lead product candidate in Phase 3 clinical development for IOP lowering in patients with open-angle glaucoma or ocular hypertension.
Read More
Machine learning sees into the future to prevent sight loss in humans
December 17th 2023A team of researchers from Tokyo Medical and Dental University have developed models based on machine learning that predict long-term visual acuity in patients with high myopia, one of the top three causes of irreversible blindness in many regions of the world.
Read More